Stanford Health Care’s Janjri Desai, Pharm.D., says pharmacists improve outcomes but often can’t bill for it, making billing parity key to growing services.
|Articles|March 20, 2014
Fact File: The truth about penicillin allergy
19 out of 20 patients who think they are allergic to penicillin are wrong and are costing 63% more
Advertisement
The truth about penicillin allergy
It is has been
- Penicillin is an antibiotic in the beta lactam family.
- 10% of patients report adverse reactions to penicillin including rash, allergic reaction and anaphylaxis.
- Many patients reporting allergies may not be allergic or their allergy may resolve over time.
- 80% of patients with a penicillin allergy will no longer be allergic 10 years after their initial reaction if they are not exposed again during this time period.
- About 90% of patients will test negative to a skin test, indicating they are not allergic to penicillin or that their previous allergy has resolved itself, however, skin testing is not 100% accurate.
Sources:
Advertisement
Related to this article
Stanford Health Care’s Janjri Desai, Pharm.D., says pharmacy should be treated as a clinical service line, not just a 340B financial workhorse.
Speakers and researchers at this year's meeting in San Diego focused on drug pricing policy, getting savings to patients at the pharmacy counter and keeping people in charge of AI.
The generic twice-yearly HIV prevention shot is expected to cost $40 a year in 120 countries, 16 months after Gilead's original approval.
Annual healthcare costs jump by almost $25,000 with targeted therapy for atopic dermatitis that avoided costs from reduced hospitalizations and ER visits only partly offset, according to recently reported research findings.
Findings from an analysis of IQVIA claims data show a prevalence rate that is five times lower than previous reports. Some of the discrepancy could be chalked up to the difference between using claims data instead of self-reporting by survey respondents.
In the MDT-BRIDGE trial, 92% of patients with stage II-III lung cancer reached surgery or chemoradiation after a midtreatment tumor board review.
Epic Research finds over half of children with type 1 diabetes miss autoantibody testing, risking misdiagnosis and limiting early treatment options like Tzield.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
New pulmonary fibrosis drugs put guidelines in focus, Prusi says | AMCP Nexus 2026
2
FDA tentatively approves first generic lenacapavir for HIV prevention in lower-income countries
3
Fewer than half of newly diagnosed children with type 1 diabetes get autoantibody testing
4
Targeted therapies for atopic dermatitis reduce hospitalizations and ER visits, but cost is a different story
5